117 related articles for article (PubMed ID: 26587865)
1. Theoretical Considerations of the Prigogine-Defay Ratio with Regard to the Glass-Forming Ability of Drugs from Undercooled Melts.
Wyttenbach N; Kirchmeyer W; Alsenz J; Kuentz M
Mol Pharm; 2016 Jan; 13(1):241-50. PubMed ID: 26587865
[TBL] [Abstract][Full Text] [Related]
2. Glass-forming ability of compounds in marketed amorphous drug products.
Wyttenbach N; Kuentz M
Eur J Pharm Biopharm; 2017 Mar; 112():204-208. PubMed ID: 27903457
[TBL] [Abstract][Full Text] [Related]
3. Computational predictions of glass-forming ability and crystallization tendency of drug molecules.
Alhalaweh A; Alzghoul A; Kaialy W; Mahlin D; Bergström CA
Mol Pharm; 2014 Sep; 11(9):3123-32. PubMed ID: 25014125
[TBL] [Abstract][Full Text] [Related]
4. Early drug development predictions of glass-forming ability and physical stability of drugs.
Mahlin D; Bergström CA
Eur J Pharm Sci; 2013 May; 49(2):323-32. PubMed ID: 23557841
[TBL] [Abstract][Full Text] [Related]
5. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
Kawakami K; Usui T; Hattori M
J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
[TBL] [Abstract][Full Text] [Related]
6. Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development.
Mahlin D; Ponnambalam S; Höckerfelt MH; Bergström CA
Mol Pharm; 2011 Apr; 8(2):498-506. PubMed ID: 21344945
[TBL] [Abstract][Full Text] [Related]
7. Influence of preparation pathway on the glass forming ability.
Blaabjerg LI; Lindenberg E; Rades T; Grohganz H; Löbmann K
Int J Pharm; 2017 Apr; 521(1-2):232-238. PubMed ID: 28232267
[TBL] [Abstract][Full Text] [Related]
8. On the theoretical determination of the Prigogine-Defay ratio in glass transition.
Tropin TV; Schmelzer JW; Gutzow I; Schick C
J Chem Phys; 2012 Mar; 136(12):124502. PubMed ID: 22462869
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.
Trasi NS; Baird JA; Kestur US; Taylor LS
J Phys Chem B; 2014 Aug; 118(33):9974-82. PubMed ID: 25076138
[TBL] [Abstract][Full Text] [Related]
10. The Prigogine-Defay ratio revisited.
Schmelzer JW; Gutzow I
J Chem Phys; 2006 Nov; 125(18):184511. PubMed ID: 17115769
[TBL] [Abstract][Full Text] [Related]
11. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
Kuentz M; Imanidis G
Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
[TBL] [Abstract][Full Text] [Related]
12. A classification system to assess the crystallization tendency of organic molecules from undercooled melts.
Baird JA; Van Eerdenbrugh B; Taylor LS
J Pharm Sci; 2010 Sep; 99(9):3787-806. PubMed ID: 20623696
[TBL] [Abstract][Full Text] [Related]
13. Relationship between crystallization tendencies during cooling from melt and isothermal storage: toward a general understanding of physical stability of pharmaceutical glasses.
Kawakami K; Harada T; Miura K; Yoshihashi Y; Yonemochi E; Terada K; Moriyama H
Mol Pharm; 2014 Jun; 11(6):1835-43. PubMed ID: 24731254
[TBL] [Abstract][Full Text] [Related]
14. Physical stability of drugs after storage above and below the glass transition temperature: Relationship to glass-forming ability.
Alhalaweh A; Alzghoul A; Mahlin D; Bergström CAS
Int J Pharm; 2015 Nov; 495(1):312-317. PubMed ID: 26341321
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters.
Nurzyńska K; Booth J; Roberts CJ; McCabe J; Dryden I; Fischer PM
Mol Pharm; 2015 Sep; 12(9):3389-98. PubMed ID: 26236939
[TBL] [Abstract][Full Text] [Related]
16. Thermal Behavior and Slow Relaxation Dynamics in Amorphous Efavirenz: A Study by DSC, XRPD, TSDC, and DRS.
Moura Ramos JJ; Piedade MFM; Diogo HP; Viciosa MT
J Pharm Sci; 2019 Mar; 108(3):1254-1263. PubMed ID: 30391416
[TBL] [Abstract][Full Text] [Related]
17. Impact of in situ granulation and temperature quenching on crystal habit and micromeritic properties of ibuprofen-cationic dextran conjugate crystanules.
Abioye AO; Kola-Mustapha A; Ruparelia K
Int J Pharm; 2014 Feb; 462(1-2):83-102. PubMed ID: 24378327
[TBL] [Abstract][Full Text] [Related]
18. Gaining Thermodynamic Insight From Distinct Glass Formation Kinetics of Structurally Similar Organic Compounds.
Kalra A; Luner P; Taylor LS; Byrn SR; Li T
J Pharm Sci; 2018 Jan; 107(1):192-202. PubMed ID: 28648689
[TBL] [Abstract][Full Text] [Related]
19. Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation.
Blaabjerg LI; Lindenberg E; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2016 Sep; 13(9):3318-25. PubMed ID: 27529364
[TBL] [Abstract][Full Text] [Related]
20. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
